查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1869590

照护现场流感诊断市场规模、份额和趋势分析报告：按检测类型、流感病毒株、技术、最终用途、地区和细分市场预测（2025-2033 年）

Point-of-Care Influenza Diagnostics Market Size, Share & Trends Analysis Report By Test Type, By Influenza Strain, By Technology, By End-use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

照护现场流感诊断市场摘要

2024 年全球照护现场流感诊断市场规模估计为 4.1556 亿美元，预计到 2033 年将达到 7.0952 亿美元。

预计从 2025 年到 2033 年，该市场将以 6.14% 的复合年增长率成长。季节性和通用流感感染疾病的发生率和严重程度增加、快速即时检测的普及、流感即时检测技术的进步以及与远端医疗和居家检测的结合是推动市场成长的主要因素。

例如，根据国际红十字会与红新月会联合会2023年10月发布的报告，每年约有10亿例季节性流感病例，其中300万至500万例为重症，导致每年29万至65万人死于呼吸道疾病。此外，2024年6月，瑞士罗氏公司（F. Hoffmann-La Roche）的cobas甲型/乙型流感及呼吸道合胞病毒核酸检测获得了美国食品食品药物管理局（FDA）的紧急使用授权（EUA）。此检测是一种在美国 liat系统上进行的甲型流感多重即时聚合酵素链锁反应（RT-PCR）检测。此检测使用小型分析仪，仅需20分钟即可得出结果，适用于大多数医疗机构，只需采集一份鼻咽拭子或前鼻拭子检体即可确诊或排除甲型和乙型流感病毒感染。

照护现场检测（POC​​）的快速普及是推动市场成长的关键因素。这些快速检测通常可在数分钟内得出结果，有助于在门诊和急诊环境中及时进行诊断和治疗决策。快速流感诊断检测（RIDT）的便利性和易用性降低了对中心检查室的依赖，缩短了出结果的时间，并改善了患者的治疗效果。此外，这些检测的价格越来越亲民，也越来越容易取得，因此可以在包括诊所、药局和急诊室在内的各种医疗机构中使用。技术的不断进步提高了快速检测的灵敏度和特异性，进一步推动了分散式检查的发展。因此，医疗机构越来越倾向于将即时检测纳入其常规流感管理流程，从而推动市场成长，尤其是在北美和欧洲，亚太地区的普及率也不断提高。

推动市场扩张的另一个创新因素是远端医疗与居家流感检测的结合。经FDA核准的居家流感检测套组通常与远端医疗平台配合使用，支援虚拟咨询，并将即时结果发送给医疗专业人员，从而实现便捷快速的居家诊断。例如，2024年10月，美国食品药物管理局（FDA）核准了Healgen Rapid Check流感A&B抗原检测试剂盒。这款非处方笺检测套组适用于出现呼吸道症状的族群，使用鼻拭子检体，可在约15分钟内提供新冠病毒和流感检测结果。此检测可辨识甲型和乙型流感病毒（引起流感的病毒）的蛋白质。

这种整合有助于公共卫生工作，促进早期发现和隔离，减少流感传播，同时提高患者接受检测的便利性和可及性。新冠肺炎疫情推动了居家诊断的发展，并提高了人们对远距医疗解决方案的认识和接受度。

目录

第一章照护现场（POC​​）流感诊断市场：调查方法与范围

第二章照护现场（POC​​）流感诊断市场：执行摘要

  • 市场概述
  • 检查类型
  • 流感病毒株概况
  • 技术概览
  • 最终用途简介
  • 竞争格局概览

第三章照护现场（POC​​）流感诊断市场变数、趋势与范围

  • 市场区隔和范围
  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
  • 市场驱动因素分析
    • 全球季节性和通用流感疫情的盛行率和严重程度不断增加
    • 快速即时检测（POC​​检测）的应用日益普及
    • 流感即时检测技术的进步
    • 整合远端医疗和居家检测
  • 市场限制因素分析
    • 先进测试设备高成本
  • 波特五力分析
  • PESTLE分析
  • 管道分析

第四章照护现场（POC​​）流感诊断市场：检测类型估算与趋势分析

  • 照护现场流感诊断市场：检测类型差异分析
  • 照护现场流感诊断市场：按检测类型分類的展望
  • 快速抗原检测（RIDT）
  • 分子就地检验
  • 基于生物感测器的检测
  • 其他的

第五章照护现场（POC​​）流感诊断市场：流感病毒株估计与趋势分析

  • 照护现场流感诊断市场：流感病毒株波动分析
  • 照护现场流感诊断市场：按流感株分類的展望
  • 甲型流感
  • 乙型流感
  • 甲型和乙型流感联合检测

第六章照护现场流感诊断市场：技术估算与趋势分析

  • 照护现场流感诊断市场：技术波动分析
  • 照护现场流感诊断市场：技术展望
  • 基于免疫检测法
  • 分子诊断
  • 基于奈米技术的系统
  • 其他的

第七章照护现场（POC​​）流感诊断市场：终端用户需求预测及趋势分析

  • 照护现场流感诊断市场：终端用途差异分析
  • 照护现场流感诊断市场：终端用户展望
  • 医院
  • 诊所
  • 居家照护环境
  • 其他的

第八章照护现场（POC​​）流感诊断市场：区域业务分析

  • 区域市场概况
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东和非洲

第九章 竞争情势

  • 公司分类
  • 策略规划
    • 新产品上市
    • 伙伴关係
    • 获得
    • 合作
    • 资金筹措
  • 主要企业市占率分析，2024 年
  • 公司热力图分析
  • 公司简介
    • Abbott
    • Becton Dickinson（BD）
    • Danaher/Cepheid
    • Quidel Corporation, Inc
    • Qiagen
    • F. Hoffmann-La Roche Ltd
    • Bio-Rad
    • BioMerieux（Biofire/Idaho Technologies）
    • Diasorin（Focus Diagnostics）
    • Hologic
    • Thermo/Remel
    • Fujirebio.
    • Visby Medical
    • Twist
Product Code: GVR-4-68040-785-8

Point-of-Care Influenza Diagnostics Market Summary

The global point-of-care influenza diagnostics market size was estimated at USD 415.56 million in 2024 and is projected to reach USD 709.52 million by 2033, growing at a CAGR of 6.14% from 2025 to 2033. Increasing global prevalence and severity of seasonal & zoonotic influenza outbreaks, growth in adoption of rapid POC tests, technological advancements in the influenza POC tests, and telehealth & home-based testing integration are key drivers of market growth.

For instance, in October 2023, the International Federation of Red Cross and Red Crescent Societies reported around a billion seasonal flu cases annually, including 3-5 million cases of severe illness, causing 290,000 to 650,000 respiratory deaths annually. Furthermore, in June 2024, F. Hoffmann-La Roche (Switzerland) received approval from the U.S. Food and Drug Administration (FDA) (Emergency Use Authorization (EUA)) for its cobas Influenza A/B & RSV nucleic acid test, an Influenza A multiplex real-time polymerase chain reaction (RT-PCR) assay on the cobas liat system. Producing results in just 20 minutes on a compact analyzer suitable for most healthcare settings, the test uses either a single nasopharyngeal or anterior nasal swab sample to confirm or rule out infection with influenza A and B viruses.

The rapid adoption of point-of-care (POC) tests is a significant factor fostering market growth. These rapid tests provide prompt results, often within minutes, allowing for timely diagnosis and treatment decisions for outpatient and urgent care settings. The convenience and ease of use of rapid influenza diagnostic tests (RIDTs) reduce reliance on centralized laboratories, reduce turnaround time, and improve patient outcomes. Furthermore, these tests are becoming more affordable and accessible, allowing their use in various healthcare settings, such as clinics, pharmacies, and emergency rooms. This shift towards decentralized testing is reinforced by ongoing technological advancements that improve the sensitivity and specificity of rapid tests. Therefore, healthcare providers are more likely to use POC testing as part of routine influenza management, driving market growth, particularly in North America and Europe, with growing adoption in Asia-Pacific markets.

Moreover, one revolutionary factor propelling market expansion is the combination of telehealth and home-based influenza testing. FDA-approved home flu test kits, which are frequently used with telehealth platforms that allow virtual consultations and real-time results transmission to healthcare professionals, have made it possible for people to perform quick diagnostics in the convenience of their own homes. For instance, in October 2024, the Healgen Rapid Check Flu A&B Antigen Test was authorized for sale by the US Food and Drug Administration. The test, available without a prescription and intended for people with respiratory symptoms, uses a nasal swab sample to provide COVID-19 and flu results at home in about 15 minutes. The test can identify proteins from influenza A and B (the viruses that cause the flu).

This integration supports public health initiatives by promoting early detection and isolation, which slows the spread of influenza, and improves patient convenience and testing accessibility. The COVID-19 pandemic made home-based diagnostics easier, raising awareness and acceptance of remote healthcare solutions.

Global Point-of-Care Influenza Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global point-of-care influenza diagnostics market based on test type, influenza strain, technology, end-use, and region:

  • Test Type Outlook (USD Million, 2021 - 2033)
  • Rapid Antigen Tests (RIDT)
  • Molecular Point-of-Care Tests
  • Biosensor-Based Tests
  • Others
  • Influenza Strain Outlook (USD Million, 2021 - 2033)
  • Influenza A
  • Influenza B
  • Influenza A & B Combined Tests
  • Technology Outlook (USD Million, 2021 - 2033)
  • Immunoassay-based
  • Molecular Diagnostics
  • Nanotechnology based Systems
  • Others
  • End-use Outlook (USD Million, 2021 - 2033)
  • Hospitals
  • Clinics
  • Homecare Settings
  • Others
  • Regional Outlook (USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Point-of-Care Influenza Diagnostics Market: Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Test Type
      • 1.1.1.2. Influenza Strain Segment
      • 1.1.1.3. Technology Segment
      • 1.1.1.4. End Use Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Influenza Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Point-of-Care Influenza Diagnostics Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Test Type
  • 2.3. Influenza Strain Snapshot
  • 2.4. Technology Snapshot
  • 2.5. End Use Snapshot
  • 2.6. Competitive Landscape Snapshot

Chapter 3. Point-of-Care Influenza Diagnostics Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers Analysis
    • 3.4.1. Increasing global prevalence and severity of seasonal and zoonotic influenza outbreaks
    • 3.4.2. Growth in adoption of rapid POC tests
    • 3.4.3. Technological advancements in the influenza POC tests
    • 3.4.4. Telehealth & home-based testing integration
  • 3.5. Market Restraint Analysis
    • 3.5.1. High cost of advanced testing equipment
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis
  • 3.8. Pipeline Analysis

Chapter 4. Point-of-Care Influenza Diagnostics Market: Test Type Estimates & Trend Analysis

  • 4.1. Point-of-Care Influenza Diagnostics Market: Test Type Movement Analysis
  • 4.2. Point-of-Care Influenza Diagnostics Market by Test Outlook (USD Million)
  • 4.3. Rapid Antigen Tests (RIDT)
    • 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4. Molecular Point-of-Care Tests
    • 4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Biosensor-Based Tests
    • 4.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Others
    • 4.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Point-of-Care Influenza Diagnostics Market: Influenza Strain Estimates & Trend Analysis

  • 5.1. Point-of-Care Influenza Diagnostics Market: Influenza Strain Movement Analysis
  • 5.2. Point-of-Care Influenza Diagnostics Market by Influenza Strain Outlook (USD Million)
  • 5.3. Influenza A
    • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4. Influenza B
    • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Influenza A & B Combined Tests
    • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Point-of-Care Influenza Diagnostics Market: Technology Estimates & Trend Analysis

  • 6.1. Point-of-Care Influenza Diagnostics Market: Technology Movement Analysis
  • 6.2. Point-of-Care Influenza Diagnostics Market by Technology Outlook (USD Million)
  • 6.3. Immunoassay-based
    • 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4. Molecular Diagnostics
    • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Nanotechnology based Systems
    • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Others
    • 6.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Point-of-Care Influenza Diagnostics Market: End Use Estimates & Trend Analysis

  • 7.1. Point-of-Care Influenza Diagnostics Market: End Use Movement Analysis
  • 7.2. Point-of-Care Influenza Diagnostics Market by End Use Outlook (USD Million)
  • 7.3. Hospitals
    • 7.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4. Clinics
    • 7.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Homecare Settings
    • 7.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Others
    • 7.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Point-of-Care Influenza Diagnostics Market: Regional Business Analysis

  • 8.1. Regional Market Snapshot
  • 8.2. North America
    • 8.2.1. North America Point-of-Care Influenza Diagnostics Market Estimates and Forecast, 2021 - 2033 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. U.S. Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.2.2.2. Key Country Dynamics
      • 8.2.2.3. Regulatory Framework
      • 8.2.2.4. Reimbursement Scenario
      • 8.2.2.5. Competitive Scenario
    • 8.2.3. Canada
      • 8.2.3.1. Canada Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.2.3.2. Key Country Dynamics
      • 8.2.3.3. Regulatory Framework
      • 8.2.3.4. Reimbursement Scenario
      • 8.2.3.5. Competitive Scenario
    • 8.2.4. Mexico
      • 8.2.4.1. Mexico Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.2.4.2. Key Country Dynamics
      • 8.2.4.3. Regulatory Framework
      • 8.2.4.4. Reimbursement Scenario
      • 8.2.4.5. Competitive Scenario
  • 8.3. Europe
    • 8.3.1. Europe Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.2. UK
      • 8.3.2.1. UK Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.2.2. Key Country Dynamics
      • 8.3.2.3. Regulatory Framework
      • 8.3.2.4. Reimbursement Scenario
      • 8.3.2.5. Competitive Scenario
    • 8.3.3. Germany
      • 8.3.3.1. Germany Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.3.2. Key Country Dynamics
      • 8.3.3.3. Regulatory Framework
      • 8.3.3.4. Reimbursement Scenario
      • 8.3.3.5. Competitive Scenario
    • 8.3.4. Spain
      • 8.3.4.1. Spain Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.4.2. Key Country Dynamics
      • 8.3.4.3. Regulatory Framework
      • 8.3.4.4. Reimbursement Scenario
      • 8.3.4.5. Competitive Scenario
    • 8.3.5. France
      • 8.3.5.1. France Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.5.2. Key Country Dynamics
      • 8.3.5.3. Regulatory Framework
      • 8.3.5.4. Reimbursement Scenario
      • 8.3.5.5. Competitive Scenario
    • 8.3.6. Italy
      • 8.3.6.1. Italy Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.6.2. Key Country Dynamics
      • 8.3.6.3. Regulatory Framework
      • 8.3.6.4. Reimbursement Scenario
      • 8.3.6.5. Competitive Scenario
    • 8.3.7. Denmark
      • 8.3.7.1. Denmark Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.7.2. Key Country Dynamics
      • 8.3.7.3. Regulatory Framework
      • 8.3.7.4. Reimbursement Scenario
      • 8.3.7.5. Competitive Scenario
    • 8.3.8. Sweden
      • 8.3.8.1. Sweden Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.8.2. Key Country Dynamics
      • 8.3.8.3. Regulatory Framework
      • 8.3.8.4. Reimbursement Scenario
      • 8.3.8.5. Competitive Scenario
    • 8.3.9. Norway
      • 8.3.9.1. Norway Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.9.2. Key Country Dynamics
      • 8.3.9.3. Regulatory Framework
      • 8.3.9.4. Reimbursement Scenario
      • 8.3.9.5. Competitive Scenario
  • 8.4. Asia Pacific
    • 8.4.1. Asia-Pacific Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.4.2. Japan
      • 8.4.2.1. Japan Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.4.2.2. Key Country Dynamics
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Reimbursement Scenario
      • 8.4.2.5. Competitive Scenario
    • 8.4.3. China
      • 8.4.3.1. China Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.4.3.2. Key Country Dynamics
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Reimbursement Scenario
      • 8.4.3.5. Competitive Scenario
    • 8.4.4. India
      • 8.4.4.1. India Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.4.4.2. Key Country Dynamics
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Reimbursement Scenario
      • 8.4.4.5. Competitive Scenario
    • 8.4.5. South Korea
      • 8.4.5.1. South Korea Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.4.5.2. Key Country Dynamics
      • 8.4.5.3. Regulatory Framework
      • 8.4.5.4. Reimbursement Scenario
      • 8.4.5.5. Competitive Scenario
    • 8.4.6. Thailand
      • 8.4.6.1. Thailand Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.4.6.2. Key Country Dynamics
      • 8.4.6.3. Regulatory Framework
      • 8.4.6.4. Reimbursement Scenario
      • 8.4.6.5. Competitive Scenario
    • 8.4.7. Australia
      • 8.4.7.1. Australia Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.4.7.2. Key Country Dynamics
      • 8.4.7.3. Regulatory Framework
      • 8.4.7.4. Reimbursement Scenario
      • 8.4.7.5. Competitive Scenario
  • 8.5. Latin America
    • 8.5.1. Latin America Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.5.2. Brazil
      • 8.5.2.1. Brazil Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.5.2.2. Key Country Dynamics
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Reimbursement Scenario
      • 8.5.2.5. Competitive Scenario
    • 8.5.3. Argentina
      • 8.5.3.1. Argentina Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.5.3.2. Key Country Dynamics
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Reimbursement Scenario
      • 8.5.3.5. Competitive Scenario
  • 8.6. MEA
    • 8.6.1. MEA Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.6.2. South Africa
      • 8.6.2.1. South Africa Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.6.2.2. Key Country Dynamics
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Reimbursement Scenario
      • 8.6.2.5. Competitive Scenario
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. Saudi Arabia Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.6.3.2. Key Country Dynamics
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Reimbursement Scenario
      • 8.6.3.5. Competitive Scenario
    • 8.6.4. UAE
      • 8.6.4.1. UAE Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.6.4.2. Key Country Dynamics
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Reimbursement Scenario
      • 8.6.4.5. Competitive Scenario
    • 8.6.5. Kuwait
      • 8.6.5.1. Kuwait Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.6.5.2. Key Country Dynamics
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Reimbursement Scenario
      • 8.6.5.5. Competitive Scenario

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Strategy Mapping
    • 9.2.1. New Product Launch
    • 9.2.2. Partnerships
    • 9.2.3. Acquisition
    • 9.2.4. Collaboration
    • 9.2.5. Funding
  • 9.3. Key Company Market Share Analysis, 2024
  • 9.4. Company Heat Map Analysis
  • 9.5. Company Profiles
    • 9.5.1. Abbott
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. Becton Dickinson (BD)
      • 9.5.2.1. Company Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Danaher/Cepheid
      • 9.5.3.1. Company Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. Quidel Corporation, Inc
      • 9.5.4.1. Company Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. Qiagen
      • 9.5.5.1. Company Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. F. Hoffmann-La Roche Ltd
      • 9.5.6.1. Company Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. Bio-Rad
      • 9.5.7.1. Company Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. BioMerieux (Biofire/Idaho Technologies)
      • 9.5.8.1. Company Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. Diasorin (Focus Diagnostics)
      • 9.5.9.1. Company Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives
    • 9.5.10. Hologic
      • 9.5.10.1. Company Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Product Benchmarking
      • 9.5.10.4. Strategic Initiatives
    • 9.5.11. Thermo/Remel
      • 9.5.11.1. Company Overview
      • 9.5.11.2. Financial Performance
      • 9.5.11.3. Product Benchmarking
      • 9.5.11.4. Strategic Initiatives
    • 9.5.12. Fujirebio.
      • 9.5.12.1. Company Overview
      • 9.5.12.2. Financial Performance
      • 9.5.12.3. Product Benchmarking
      • 9.5.12.4. Strategic Initiatives
    • 9.5.13. Visby Medical
      • 9.5.13.1. Company Overview
      • 9.5.13.2. Financial Performance
      • 9.5.13.3. Product Benchmarking
      • 9.5.13.4. Strategic Initiatives
    • 9.5.14. Twist
      • 9.5.14.1. Company Overview
      • 9.5.14.2. Financial Performance
      • 9.5.14.3. Product Benchmarking
      • 9.5.14.4. Strategic Initiatives

List of Tables

  • Table 1 List Of Secondary Sources
  • Table 2 List Of Abbreviation
  • Table 3 Global Point-of-Care Influenza Diagnostics Market, By Region, 2021 - 2033 (USD Million)
  • Table 4 Global Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 5 Global Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 6 Global Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 7 Global Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 8 North America Point-of-Care Influenza Diagnostics Market, By Country, 2021 - 2033 (USD Million)
  • Table 9 North America Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 10 North America Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 11 North America Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 12 North America Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 13 U.S. Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 14 U.S. Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 15 U.S. Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 16 U.S. Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 17 Canada Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033, (USD Million)
  • Table 18 Canada Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033, (USD Million)
  • Table 19 Canada Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033, (USD Million)
  • Table 20 Canada Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 21 Mexico Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 22 Mexico Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 23 Mexico Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 24 Mexico Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 25 Europe Point-of-Care Influenza Diagnostics Market, By Country, 2021 - 2033, (USD Million)
  • Table 26 Europe Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 27 Europe Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 28 Europe Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 29 Europe Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 30 UK Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 31 UK Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 32 UK Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 33 UK Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 34 Germany Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 35 Germany Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 36 Germany Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 37 Germany Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 38 France Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 39 France Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 40 France Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 41 France Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 42 Italy Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 43 Italy Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 44 Italy Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 45 Italy Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 46 Spain Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 47 Spain Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 48 Spain Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 49 Spain Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 50 Sweden Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 51 Sweden Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 52 Sweden Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 53 Sweden Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 54 Norway Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 55 Norway Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 56 Norway Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 57 Norway Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 58 Denmark Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 59 Denmark Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 60 Denmark Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 61 Denmark Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 62 Asia Pacific Point-of-Care Influenza Diagnostics Market, By Country, 2021 - 2033, (USD Million)
  • Table 63 Asia Pacific Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 64 Asia Pacific Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 65 Asia-Pacific Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 66 Asia Pacific Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 67 Japan Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 68 Japan Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 69 Japan Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 70 Japan Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 71 China Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 72 China Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 73 China Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 74 China Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 75 India Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 76 India Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 77 India Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 78 India Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 79 Australia Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 80 Australia Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 81 Australia Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 82 Australia Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 83 Thailand Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 84 Thailand Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 85 Thailand Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 86 Thailand Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 87 South Korea Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 88 South Korea Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 89 South Korea Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 90 South Korea Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 91 Latin America Point-of-Care Influenza Diagnostics Market, By Country, 2021 - 2033, (USD Million)
  • Table 92 Latin America Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 93 Latin America Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 94 Latin America Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 95 Latin America Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 96 Brazil Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 97 Brazil Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 98 Brazil Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 99 Brazil Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 100 Argentina Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 101 Argentina Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 102 Argentina Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 103 Argentina Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 104 MEA Point-of-Care Influenza Diagnostics Market, By Country, 2021 - 2033, (USD Million)
  • Table 105 MEA Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 106 MEA Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 107 MEA Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 108 MEA Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 109 South Africa Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 110 South Africa Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 111 South Africa Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 112 South Africa Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 113 Saudi Arabia Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 114 Saudi Arabia Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 115 Saudi Arabia Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 116 Saudi Arabia Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 117 UAE Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 118 UAE Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 119 UAE Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 120 UAE Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 121 Kuwait Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 122 Kuwait Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 123 Kuwait Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 124 Kuwait Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Market summary
  • Fig. 4 Market segmentation & scope
  • Fig. 5 Market size and growth prospects
  • Fig. 6 Global Point-of-Care Influenza Diagnostics Market - Key market driver analysis
  • Fig. 7 Global Point-of-Care Influenza Diagnostics Market - Key market restraint analysis
  • Fig. 8 Penetration & growth prospect mapping
  • Fig. 9 Global Point-of-Care Influenza Diagnostics Market - Porter's analysis
  • Fig. 10 Global Point-of-Care Influenza Diagnostics Market - PESTEL analysis
  • Fig. 11 Global Point-of-Care Influenza Diagnostics Market: Test Type outlook key takeaways
  • Fig. 12 Global Point-of-Care Influenza Diagnostics Market: Test Type movement analysis
  • Fig. 13 Rapid Antigen Tests (RIDT) Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 14 Molecular Point-of-Care Tests Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 15 Biosensor-Based Tests Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 16 Others Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 17 Global Point-of-Care Influenza Diagnostics Market Technology outlook key takeaways
  • Fig. 18 Global Point-of-Care Influenza Diagnostics Market: Technology movement analysis
  • Fig. 19 Influenza A Point-of-Care Influenza Diagnostics Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 20 Influenza B Point-of-Care Influenza Diagnostics Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 21 Influenza A & B Combined Tests Point-of-Care Influenza Diagnostics Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 22 Global Point-of-Care Influenza Diagnostics Market: Technology outlook key takeaways
  • Fig. 23 Global Point-of-Care Influenza Diagnostics Market: Technology movement analysis
  • Fig. 24 Immunoassay-based Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 25 Molecular Diagnostics Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 26 Nanotechnology based Systems Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 27 Others Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 28 Global Point-of-Care Influenza Diagnostics Market: End Use outlook key takeaways
  • Fig. 29 Global Point-of-Care Influenza Diagnostics Market: End Use movement analysis
  • Fig. 30 Hospitals Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 31 Clinics Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 32 Homecare Settings Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 33 Others Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 34 Regional marketplace: Key takeaways
  • Fig. 35 Global Point-of-Care Influenza Diagnostics Market: Regional movement analysis
  • Fig. 36 North America Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 37 U.S. Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 38 Canada Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 39 Mexico Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 40 Europe Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 41 UK Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 42 Germany Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 43 France Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 44 Spain Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 45 Italy Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 46 Denmark Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 47 Sweden Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 48 Norway Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 49 Asia Pacific Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 50 Japan Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 51 China Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 52 India Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 53 South Korea Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 54 Australia Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 55 Thailand Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 56 Latin America Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 57 Brazil Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 58 Argentina Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 59 MEA Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 60 South Africa Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 61 Saudi Arabia Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 62 UAE Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 63 Kuwait Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 64 Strategy framework